This week, the FDA issued draft guidance to encourage cannabis-related clinical research. We love to see news like this, because we’ve been sponsoring and advocating for veterinary CBD research since the early days of the industry. When everyone else was rushing to slap a cute pet label on a bottle of CBD that might (or might not) contain what the label says it contains, we were out there doing the hard work. Meeting with the scientists and veterinarians at Colorado State University’s College of Veterinary Medicine, sponsoring safety trials and and pharmacokinetics research, and helping to launch Phase 2 efficacy trials for epilepsy and arthritis takes a vast amount of resources, but we’ve been committed from the get-go to doing this right.
Clinical research on the benefits of CBD oil for pets is the reason our company exists. We hear so many stories from our customers about the ways that our CBD oil helps their pets, and we think all those stories deserve to be investigated. That’s why we’re launching a foundation to focus exclusively on raising funds for more research. You’ll hear more from us soon about the foundation, so stay tuned. In the meantime, you can read more about our research and all the veterinary clinical trials here.
As the CBD industry shifts from a “Wild West” mentality to a more regulated and mature industry, the FDA will play an increasing role. Encouraging clinical research—and offering guidelines—is an important step, and one that we welcome. FDA Principal Deputy Commissioner Amy Abernethy M.D., Ph.D described the FDA’s new guidance in a press release issued by the agency:
“A range of stakeholders have expressed interest in development of drugs that contain cannabis and compounds found in cannabis. Recent legislative changes have also opened new opportunities for cannabis clinical research. As that body of research progresses and grows, the FDA is working to support drug development in this area. It is critical that the FDA continues to do what we can to support the science needed to develop new drugs from cannabis. The FDA believes the drug approval process represents the best way to ensure that safe and effective new medicines, including any drugs that contain cannabis or cannabis-derived compounds, are available to patients in need of appropriate medical therapy. It is critical that the FDA continues to do what we can to support the science needed to develop new drugs from cannabis. The FDA believes the drug approval process represents the best way to ensure that safe and effective new medicines, including any drugs that contain cannabis or cannabis-derived compounds, are available to patients in need of appropriate medical therapy.“FDA In Brief: FDA Issues Draft Guidance to Encourage Cannabis-Related Clinical Research, July 21, 2020. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-issues-draft-guidance-encourage-cannabis-related-clinical-research
Three cheers for more FDA involvement in the CBD industry, more accountability from producers, and most importantly, MORE CLINICAL RESEARCH! This is music to our ears.
Want to try to most rigorously researched and tested CBD oil for your pet? Visit the shop, or reach out to firstname.lastname@example.org with any questions!
Nutraceuticals in Veterinary Medicine covers ABSC Organics’ clinical trials at Colorado State University in Cannabis Chapter
We’re delighted to see the CBD clinical safety and efficacy trials we’ve sponsored at CSU highlighted in the recently published Nutraceuticals in Veterinary Medicine textbook. With over sixty chapters covering supplements and their use in animals, this textbook from Springer is a comprehensive resource for veterinarians and researchers. Chapter 10—entitled “Cannabis in Veterinary Medicine: Cannabinoid Therapies for Animals—delves deep in the science and research around veterinary use of cannabis and CBD.
Comprehensive Treatment of Veterinary CBD Use
The chapter covers everything from the history of veterinary cannabis use and regulatory and legal considerations to a deep dive into the chemistry of the cannabis plant and the pharmacology of cannabinoids such as cannabidiol (CBD). Highlighted topics include:
- The 2018 Farm Bill and its effects on industry and research
- Detailed look at the endocannabinoid system (including a terrific graphic illustrating the feedback loop for the endocannabinoid signaling system)
- Nutritional value of Cannabis/Hemp seed oil – Fatty acid profile has anti-inflammatory properties
- Review of the endocannabinoid system (ECS) in humans – including beneficial effects for sleep, anxiety and stress, obesity and metabolic disorders, cancer, and inflammatory conditions
- Review of the ECS in animals – focuses on dogs but touches on all mammals, birds, fish, and even invertebrates
- Phytocannabinoids, terpenes, and the Entourage effect (importance of full spectrum CBD product to achieve synergistic benefits from all compounds)
- Good manufacturing processes and the importance of organic hemp
- The importance of third party lab testing for potency and contamination
- Completed and ongoing clinical trials at Colorado State University and Cornell
Clinical Trials at CSU Featured
Beginning on page 140 (Section 6) the authors cover the Colorado State University clinical trials in impressive detail. They discuss everything from the Phase One safety study to the efficacy studies for epilepsy and osteoarthritis. We are thrilled to see everything we are learning with Dr. McGrath and her team at CSU consolidated in a textbook that will inform veterinarians for years to come.
Cannabis Chapter Available on FDA Website
Currently, you can view the entire Cannabis chapter on the FDA’s website here. The authors submitted the paper as part of the public comment process for the FDA’s Proposed Rule: Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments.
Every time our research is published, we advance the CBD knowledge bar a little further. Our goal is to keep researching CBD to provide optimized dosing recommendations and determine even more applications for the powerful supplement. As we keep learning, we’ll keep sharing the news and knowledge with you here on our blog, so stay tuned!
Need to purchase ABSC Pure Organic CBD Oil™ for your pet? Shop now!
“Promising” Epilepsy Trial Results Published in June 1 Issue of the Journal of the American Veterinary Association
We first reported on the encouraging preliminary results of Dr. Stephanie McGrath’s epilepsy trial last year. Now, the complete results of this groundbreaking pilot study have been published in the Journal of the American Veterinary Association’s June 1 issue. If you’ve got a pet with epilepsy, you’re going to want to pay attention to this study!
Clinical Trial Backs Up Anecdotal Evidence
We’ve been hearing from customers for years that our Pure Organic CBD Oil helps reduce the severity, frequency, and duration of seizures in their epileptic pets. We get thank you notes, rave reviews, and even videos that show the beneficial effects of our product. Now, we’re starting to see the fruits of our research in the form of clinical trial results.
Pilot Study Shows Significant Reduction in Seizures with CBD Treatment
Twenty six dogs with intractable idiopathic epilepsy were initially enrolled in the pilot study. After exclusions, sixteen dogs completed the 12-week trial. In this double blind study, the dogs were randomly assigned to a CBD group or placebo group. The CBD group received ABSC’s CBD-infused oil twice daily for 12 weeks while continuing their existing antiepileptic treatments. The placebo group received oil without CBD, and also continued their existing medications. All other parameters were consistent for both groups. Dr. McGrath and her colleagues at CSU compared seizure activity, adverse effects, and plasma CBD concentrations over the course of the twelve weeks, and found that 89% of the dogs in the CBD group saw a reduction in seizure frequency. Researchers also found a strong correlation between plasma (blood) CBD concentration and seizure frequency. Further studies will evaluate whether higher doses of CBD decrease seizure activity even further.
These results are groundbreaking when it comes to veterinary CBD usage, and they are generating lots of buzz in the veterinary community and beyond. Check out Dr. McGrath–and a nice closeup of our product (old label)–on the news in Denver:
More CBD Trials to Come
Based on the exciting results from this pilot study, Dr. McGrath is currently working on a larger epilepsy study supported by the AKC Canine Health Foundation. Stay tuned for more promising results, and visit the AKC Canine Health Foundation site to learn how you can help with their research initiatives. In the meantime you can purchase the very same CBD product used in Dr. McGrath’s study for your pet here at petpainfree.com. Whether your pet suffers from epilepsy, arthritis, inflammation, anxiety, or another disorder, ABSC Pure Organic CBD Oil may be able to provide relief.
ABSC Organics Cares Enough to Do the Research
At ABSC Organics, we put our money where our mouth is. We partner with some of the world’s best veterinary researchers because we believe in our product and in the power of CBD. Want to learn more about past, current, and future clinical trials with ABSC Pure Organic CBD Oil? Check out our Clinical Trial page for more info!
Assessment of Safety, Toxicity, and Pharmacokinetics of Cannabidiol in Healthy Dogs
Have you ever wanted to know more about ABSC and how we came to be involved with clinical trials at CSU? We’re pulling a video out of the archives today to share with you! This short video of Veterinary Neurologist Dr. Stephanie McGrath speaking at a conference at CSU Pueblo in 2017 highlights her work on safety, toxicity, and pharmacokinetics of CBD. During her talk, Dr. McGrath discusses her interest in testing CBD for dogs and her concerns with unregulated and untested CBD products. She needed a safe and pure product to run trials with, and ABSC wanted to support advanced research in the field. It was a match made in heaven, and the rest is history!
ABSC Pure Organic CBD Oil™ For Dogs Used in More Clinical Trials
Aided in large part by the commitment and investment of science-driven firms like ABSC Organics, cannabis research for veterinary patients is cautiously advancing. Dr. Stephanie McGrath, a neurologist and assistant professor at Colorado State University’s College of Veterinary Medicine & Biomedical Sciences, is on the forefront of veterinary cannabidiol research. She has completed two recent clinical studies on the effects of cannabidiol in dogs with epilepsy or osteoarthritis. This work was recently published in The Journal of the American Veterinary Association:
“An initial investigation involving 30 healthy research animals found that CBD was tolerated and resulted in measurable blood concentrations. Dr. McGrath expects results of that study will be published this year. Data from the other studies are being analyzed, but preliminary results of the epilepsy investigation were promising enough that, in January, Dr. McGrath began a three-year crossover study of CBD for epilepsy in dogs with a $350,000 grant from the American Kennel Club.”
ABSC Organics is a Proud Partner in Advancing the Field of Veterinary CBD Research
ABSC Organics provided the funding and CBD oil for Dr. McGrath’s study. We are deeply committed to raising the bar for research and analysis in this arena, and we are proud to partner with the scientists who are leading the push for better data and rigorous clinical analysis.
ABSC Pure Organic CBD Oil Used in Pilot Epilepsy Study at Colorado State University
Great news out of Dr. McGrath’s lab at Colorado State University! Dr. McGrath–a veterinary neurologist at the University’s James L. Voss Teaching Hospital–conducted a double-blind pilot study using ABSC Pure Organic CBD Oil™ to look at using CBD to treat dogs with epilepsy. Calling her preliminary results “very promising,” Dr. McGrath reports that 89% of the dogs in the small pilot study showed a reduction in seizure frequency.
Sixteen dogs were enrolled in the clinical trial. Nine dogs were treated with CBD, which has 0.3 percent or less of the psychoactive component of cannabis, THC; seven dogs in a control group were treated with a placebo. The compound is not considered marijuana and can be used for research purposes based on the 2014 United States Department of Agriculture Farm Bill.Giuden, Mary. July 19, 2019. Preliminary data from CBD clinical trials ‘promising.’ News from the College of Veterinary Medicine and Biomedical Sciences. https://cvmbs.source.colostate.edu/preliminary-data-from-cbd-clinical-trials-promising/
We Care Enough To Do the Research
We are thrilled to be part of Dr. McGrath’s research, and to see these encouraging results with canine epilepsy patients. Although we have many anecdotal stories about CBD’s ability to reduce the frequency and severity of seizures, it’s important that we continue to gather clinical research and evidence. That’s why we will always support researchers like Dr. McGrath, who are leading the charge for more knowledge about CBD.
More Clinical Trials
Dr. McGrath and her colleagues at Colorado State have launched a larger clinical trial for epilepsy, and are seeking to enroll 60 dogs. You can learn more about that trial, including how to enroll, at the teaching hospital’s website. Want to learn more about other clinical trials happening with ABSC Pure Organic CBD Oil? You can visit our News & Research page for updates on all the exciting things happening with veterinary CBD research!
Influencers & Bloggers
Are you a blogger or influencer and want to collaborate with us because you care as much about pets as we do? We would love to hear from you. email@example.com
Are you an affiliate marketer who would like to promote the benefits of a scientifically-tested CBD oil for pets? Share your ideas with us.